ADA and rheumatoid arthritis: Increasing the weekly dosage is also an effective strategy for patients with rheumatoid arthritis and ulcerative colitis who do not respond to ADA, as evidenced by studies by Bartelds et al. [55], Wolf et al. [56], and Bartelds et al. [57], and similar conclusions have been reached in studies focusing on NIU [26].